Development and Validation of a Clinical Prognostic Model Based on Immune-Related Genes Expressed in Clear Cell Renal Cell Carcinoma

Shiqi Ren1,2†, Wei Wang1,2†, Hanyu Shen3†, Chenlin Zhang4, Haiyan Hao5, Mengjing Sun1,6, Yingjing Wang1,6, Xiaojing Zhang1, Bing Lu1, Chen Chen7* and Ziheng Wang1*

1 Department of Clinical Biobank, Nantong University Affiliated Hospital, Nantong, China, 2 Department of Medicine, Nantong University Xinling College, Nantong, China, 3 Medical School of Nantong University, Nantong, China, 4 Department of Orthopaedics, Qidong Hospital of Chinese Medicine, Nantong, China, 5 Department of Urology, Affiliated Hospital of Nantong University, Nantong, China, 6 Department of Pathology, Medical School of Nantong University, Nantong, China, 7 Department of Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China

Background: Clear cell renal cell carcinoma (ccRCC) is the most frequent and terminal subtype of RCC. Reliable markers associated with the immune response are not available to predict the prognosis of patients with ccRCC. We exploited the extensive number of ccRCC samples from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) repository to perform a comprehensive analysis of immune-related genes (IRGs).

Methods: Based on TCGA data, we incorporated IRGs and their expression profiles of 72 normal and 539 ccRCC samples. Univariate Cox analysis was used to evaluate the relationship between overall survival (OS) and IRGs expression. The Lasso Cox regression model identified prognostic genes used to establish a clinical immune prognostic model. The TF–IRG network was used to study the potential molecular mechanisms of action and properties of ccRCC-specific IRGs. Multivariate Cox analysis established a clinical prognostic model of IRGs.

Results: We found a significant correlation among 15 differentially expressed IRGs with the OS of patients with ccRCC. Gene function enrichment analysis showed that these IRGs are significantly associated with response to receptor ligand activity. Lasso Cox regression analysis identified 10 genes with the greatest prognostic value. A clinical prognostic model based on six IRGs, which performed well for predicting prognosis, revealed significant associations of patients’ survival with age, sex, stage, tumor, node, and metastasis. Moreover, these findings reflect the infiltration of tumors by various immune cells.

Conclusion: We identified six clinically significant IRGs and incorporated them into a clinical prognostic model with great significance for monitoring and predicting prognosis of ccRCC.

Keywords: clear cell renal cell carcinoma, TCGA, GEO, immune-related genes, clinical prognostic model, tumor microenvironment
INTRODUCTION

Renal cell carcinoma (RCC) is a frequent cause of mortality of patients with urinary cancer, accounting for 2% of malignant tumors of adults (1). Annually, there are ~350,000 new cases of RCC worldwide, leading to ≥140,000 annual fatalities (2). Clear cell renal cell carcinoma (ccRCC) is the most frequent and lethal subtype, accounting for 75% of RCCs (3). Although the treatment of ccRCC has significantly improved during the past 10 years, there are limitations to its diagnosis, treatment, and prognosis. Distant metastasis occurs in 30% of patients with ccRCC who undergo surgery during the early stages of disease (4). Further studies of the mechanisms of ccRCC occurrence and development are therefore required, as well as efforts to develop new diagnostic methods and to identify potential biomarkers.

The components of the tumor microenvironment, which contribute to the development of tumors, include immune cells, stromal cells, extracellular matrix molecules, cytokines, and chemokines (5). These components reflect the evolutionary nature of tumor progression, which promotes immune escape, tumor growth, and metastasis (6). Moreover, new therapeutic targets have been identified through studies of these components and their complex interactions (5). For example, Li et al. (7) investigated the prognostic value of immune-related genes (IRGs) to establish an individual’s immune characteristics and to improve predictions of the prognosis of patients with non-small cell lung cancer (7). Thus, understanding the molecular and cellular composition and function of the ccRCC tumor microenvironment is required to improve prognosis and to identify new biomarkers (8, 9).

FIGURE 1 | Differentially expressed immune-related genes. Heatmap (A) and volcano plot (B) showing genes differentially expressed between clear cell renal cell carcinoma (ccRCC) and normal tissues. Green, red, and black dots represent genes expressed at relatively lower, higher, or equal levels. The differentially expressed immune-related genes (IRGs) are shown in a heatmap (C) and volcano plot (D). Green, red, and black dots represent genes expressed at relatively lower, higher, or equal levels.
Publicly available gene expression datasets and the emergence of related platforms such as The Cancer Genome Atlas (TCGA) database provide readily accessible and convenient platforms for rapid and accurate identification of biomarkers for monitoring tumors (10, 11). For example, Yoshihara et al. (8) studied the tumor microenvironment by analyzing the expression of specific molecular biomarkers of immune and stromal cells using an estimation algorithm employing stromal and immune scores. Such estimation algorithms evaluate the prognosis of many tumors and identify biomarkers (8, 9, 12, 13). However, there is no definitive threshold to aid studies of the associations of clinical correlates and prognostic significance with the tumor microenvironment and ccRCC.

Here we aimed to comprehensively study the possible clinical efficacy of IRGs in the ccRCC tumor microenvironment to stratify prognosis, as well as their potential value as biomarkers for targeted therapy. For this purpose, we combined the expression profiles of IRGs with clinical information to evaluate overall survival (OS). We systematically analyzed the expression of ccRCC IRGs and their associations with prognosis to develop personalized prognostic markers. Furthermore, bioinformatics analysis was used to identify potential regulatory mechanisms. The results of this study will provide the basis for research related to immunization and provide a theoretical basis for the development of individualized therapy.

### MATERIALS AND METHODS

#### Data Collection and Clinical Samples

We acquired ccRCC transcriptomic sequencing data from TCGA data (https://portal.gdc.cancer.gov/), including 539 ccRCC and 72 normal samples. Patients’ clinical information was extracted as well. Gene expression matrix files and clinical information from the GSE29609 dataset were obtained from the Gene Expression Omnibus (GEO) repository. The list of IRGs was exported

| Ontology ID | Description | p.adjust | Count |
|-------------|-------------|-----------|-------|
| GO:0002480 | Adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 3.78E-106 | 138 |
| GO:0002449 | Lymphocyte mediated immunity | 8.76E-106 | 136 |
| GO:0002429 | Immune response-activating cell surface receptor signaling pathway | 1.69E-94 | 137 |
| GO:0002788 | Immune response-regulating cell surface receptor signaling pathway | 1.76E-93 | 140 |
| GO:0016064 | Immunoglobulin mediated immune response | 1.76E-93 | 105 |
| GO:0019724 | B cell mediated immunity | 2.81E-93 | 105 |
| GO:0006959 | Humoral immune response | 3.63E-92 | 126 |
| GO:0002455 | Humoral immune response mediated by circulating immunoglobulin | 3.63E-92 | 91 |
| GO:0006958 | Complement activation, classical pathway | 3.20E-90 | 87 |
| GO:0050900 | Leukocyte migration | 1.36E-85 | 137 |
| GO:0009897 | External side of plasma membrane | 1.98E-83 | 118 |
| GO:0042571 | Immunoglobulin complex, circulating | 2.99E-59 | 52 |
| GO:0019814 | Immunoglobulin complex | 2.99E-59 | 53 |
| GO:0042611 | MHC protein complex | 4.97E-26 | 21 |
| GO:0043235 | Receptor complex | 1.18E-24 | 64 |
| GO:0072562 | Blood microparticle | 7.47E-21 | 37 |
| GO:0071556 | Integral component of luminal side of endoplasmic reticulum membrane | 7.81E-17 | 17 |
| GO:0098553 | Luminal side of endoplasmic reticulum membrane | 7.61E-17 | 17 |
| GO:0042613 | MHC class II protein complex | 8.96E-16 | 13 |
| GO:012507 | ER to Golgi transport vesicle membrane | 2.60E-11 | 18 |
| GO:0003823 | Antigen binding | 9.43E-163 | 140 |
| GO:0048018 | Receptor ligand activity | 7.44E-75 | 124 |
| GO:0034987 | Immunoglobulin receptor binding | 2.39E-57 | 52 |
| GO:0005125 | Cytokine activity | 6.65E-54 | 75 |
| GO:005126 | Cytokine receptor binding | 3.96E-45 | 75 |
| GO:0004896 | Cytokine receptor activity | 6.41E-36 | 42 |
| GO:0042522 | Serine-type endopeptidase activity | 4.44E-35 | 62 |
| GO:008236 | Serine-type peptidase activity | 9.84E-33 | 62 |
| GO:0017171 | Serine hydrolase activity | 2.15E-32 | 62 |
| GO:0008083 | Growth factor activity | 2.70E-29 | 47 |
from the immunology database and analysis portal (ImmPort) database that provides immunology data (14). Moreover, the database provides a list of IRGs associated with processes that mediate the immune response.

### Analysis of Differentially Expressed Genes

The edgeR package was used to screen IRGs differentially expressed between ccRCC and normal samples (15). Log2 transformation was used to standardize the raw data. We applied differential gene expression (DGE) analysis using cut-off values of $|\log_2$ fold change $| > 1$ and FDR $< 0.05$. Then, we extracted the differentially expressed IRGs from all DEGs. The molecular mechanisms potentially responsible for the differential expression of IRGs were investigated using functional enrichment analysis of the GO and KEGG pathways (16–18) using the clusterProfiler package (19).

### Survival Analysis

Clinical information were acquired from TCGA data and the GEO database. To analyze OS, we used the R survival and survminer packages. We conducted single-variable Cox analysis using the R survival package to identify survival-related IRGs.

### Molecular Characteristics of Prognosis-Related IRGs

Analyses of the differential expression of IRGs related to the prognosis of patients with ccRCC may have clinical value. To investigate functional interactions, we constructed a protein–protein interaction (PPI) network using the STRING database (http://string-db.org) (20). PPI networks show direct or indirect interactions of gene products. Cytoscape was used to visualize the results of the PPI network (21). Moreover, transcription factors (TFs) directly control gene expression. We focused on potential target transcription factors (TFs) of these prognosis-related IRGs. To identify the regulatory links between the TFs and the transcriptome, we employed the Cistrome Cancer database (http://cistrome.org/), which incorporates TCGA data with >2,300 ChIP-seq data and analyses of chromatin accessibility. We constructed a regulatory network of potential TFs and current IRGs by considering TFs of clinical significance.

### Construction and Verification of a Prognostic Model

We used the Lasso method to select the main IRGs from the important cohort of the Cox univariate regression analysis, which identifies the subclass of IRGs associated with the prognosis with ccRCC. This was achieved by considering lowering the regression coefficient by suppressing the penalty score compared with its size. Finally, a few indicators with nonzero weights persisted, while those of most possible indicators approached zero. Therefore, the proportional hazards regression calculated using the Lasso method further reduced the representation of immune-related genes. We next generated a sample of an existing sample dataset using 1,000 iterations, selected IRGs repeated 900 times, and used the “glmetric” R package to complete the Lasso Cox analysis. Finally, we used $\beta$ coefficients of multiple regression analysis to establish a prognostic immune correlation model. These coefficients were multiplied by the expression level of each immune-related gene.

### Table 2

| ID          | Description                                   | $P_{\text{adj}}$ | Count |
|-------------|-----------------------------------------------|-----------------|-------|
| hsa04060    | Cytokine–cytokine receptor interaction        | 1.88E-67        | 117   |
| hsa04061    | Viral protein interaction with cytokine and cytokine receptor | 1.41E-35        | 52    |
| hsa04650    | Natural killer cell mediated cytotoxicity     | 2.82E-25        | 49    |
| hsa04612    | Antigen processing and presentation           | 4.09E-21        | 35    |
| hsa04640    | Hematopoietic cell lineage                    | 4.17E-18        | 36    |
| hsa04658    | Th1 and Th2 cell differentiation              | 1.93E-16        | 33    |
| hsa04652    | Chemokine signaling pathway                   | 1.97E-15        | 46    |
| hsa04659    | Th17 cell differentiation                     | 3.35E-15        | 34    |
| hsa04514    | Cell adhesion molecules (CAMs)                | 5.70E-13        | 37    |
| hsa04630    | JAK-STAT signaling pathway                   | 1.31E-11        | 37    |

*LogFC, log fold change (tumor tissues vs. normal tissues); FDR, false discovery rate.*

### Table 3

| Gene symbol | logFC | $p$-value | FDR |
|-------------|-------|-----------|-----|
| AEN         | 1.39002 | <0.001 | <0.001 |
| ANGPTL7     | -1.06387 | <0.001 | <0.001 |
| APLN        | 2.486788 | <0.001 | <0.001 |
| AZGP1       | -1.75511 | <0.001 | <0.001 |
| BLNK        | -1.15577 | <0.001 | <0.001 |
| BMP5        | -1.27325 | <0.001 | <0.001 |
| BMP8A       | 1.442843 | <0.001 | <0.001 |
| C3AR1       | 1.909827 | <0.001 | <0.001 |
| CARD11      | 2.086722 | <0.001 | <0.001 |
| CKLF        | 1.085822 | <0.001 | <0.001 |
| CSF3R       | 2.789211 | <0.001 | <0.001 |
| EB13        | 2.313785 | <0.001 | <0.001 |
| FAM3B       | -4.0026 | <0.001 | <0.001 |
| FCGR2B      | 2.001925 | <0.001 | <0.001 |
| FPR1        | 1.584903 | <0.001 | <0.001 |
| HCST        | 1.980888 | <0.001 | <0.001 |
| HSPAl       | 2.069337 | <0.001 | <0.001 |
| IGHA2       | 2.137115 | <0.001 | <0.001 |
| IGHV2       | 2.46991 | <0.001 | <0.001 |
| IL2RA       | 2.276302 | <0.001 | <0.001 |
| INPP5D      | 1.711738 | <0.001 | <0.001 |
| PPARA       | -1.00738 | <0.001 | <0.001 |
| RAET1E      | -1.80059 | <0.001 | <0.001 |
| TNFSF14     | 3.76326 | <0.001 | <0.001 |

*LogFC, log fold change (tumor tissues vs. normal tissues); FDR, false discovery rate.*
Clinical and Immune Correlations of the Prognostic Model

The classification of patients into high- and low-risk groups was performed according to their risk scores, and prognosis was evaluated. The TIMER database (https://cistrome.shinyapps.io/timer/) analyzes and visualizes the abundance of tumor-infiltrating immune cells (22). Here we analyzed these data for patients with ccRCC and calculated their correlations with IRGs to establish a model of clinical prognosis and immune cell infiltration.

Statistical Analysis

We identified the functions of the prognostic features using the survivalROC R package to calculate survival according to the area under the curve (AUC) of the receiver operator characteristic (ROC) curve (23). Significant and acceptable predictive values were defined as $AUC \geq 0.75$ and $AUC \geq 0.6$, respectively.

FIGURE 2 | Identification of immune-related genes with the most significant prognostic value. (A) Forest plot of hazard ratios showing the prognostic value of survival-related immune-related genes. (B) Gene function enrichment (GO) analysis of survival-related immune-related genes. (C,D) The Lasso regression method based on the glmnet package was used to identify the 21 most prognostic IRGs in TCGA training group.
Statistical analysis was performed using R software, and $P < 0.05$ indicates a significant difference.

**RESULTS**

**Identification of Differentially Expressed IRGs**

We extracted 7,369 genes and 611 samples from TCGA ccRCC data, including 1,902 upregulated genes and 5,467 downregulated genes (Figures 1A,B). We extracted 681 differentially expressed IRGs from this set of genes, which included 116 downregulated and 565 upregulated genes (Figures 1C,D). Gene function enrichment analysis showed that the immune response-regulating cell surface receptor signaling pathway, the external side of the plasma membrane, and antigen binding were the most common biological terms among biological processes, cell components, and molecular functions, respectively (Table 1). Furthermore, KEGG pathway analysis revealed that these IRGs (Table 2) are significantly involved in cytokine–cytokine receptor interactions, viral protein interactions with cytokines, and natural killer cell-mediated cytotoxicity. Table 3 showed the first reported IRGs in ccRCC.

**Identification of Prognosis-Related IRGs**

We found a significant association of 15 IRGs with OS. A forest hazard map shows that most of these IRGs serve as risk factors for ccRCC (Figure 2A), and gene function enrichment analysis revealed that these IRGs are significantly associated with response to receptor ligand activity (Figure 2B). Furthermore, Lasso Cox regression analysis identified 10 genes with the highest prognostic values (Figures 2C,D).

![Figure 3](image-url) | Construction of a TF–immune-related gene regulatory network. Differentially expressed transcription factors (TFs) are shown in a heatmap (A) and a volcano plot (B). Green, red, and black dots represent genes expressed at relatively lower, higher, or equal levels. (C) A regulatory network comprising TFs and IRGs. Triangles represent TFs, and red and green indicate risk and protective factors, respectively.
A Gene Regulatory Network Comprising TFs and IRGs
We next analyzed the regulatory mechanisms of TF genes and IRGs to identify the molecular mechanisms linked to their clinical significance. When we analyzed the expression profiles of 318 TFs, we identified 60 differentially expressed TFs (Figures 3A,B). A regulatory network constructed using these 60 TFs and 15 IRGs. The critical values were correlation coefficient = 0.4 and P = 0.6. The resulting TF-based regulatory networks clearly illustrated the regulatory relationships between these IRGs (Figure 3C).

Development of a Clinical Prognostic Model
Here we identified six IRGs according to the results of the Lasso Cox model analysis, which were used to develop a prognostic model of the IRGs, ANGPTL3, IL2RA, PPARA, SHC1, TGFA, and TNFSF14 (Table 4). The risk score was calculated as follows: [expression level ANGPTL3 * (-0.1200)] + [expression level IL2RA * (0.0577)] + [expression level PPARA * (-0.1445)] + [expression level SHC1 * (0.0105)] + [expression level TGFA * (-0.0159)] + [expression level TNFSF14 * (0.1075)].

### Table 4: Information on IRGs used to construct clinical prognostic models.

| IRGs    | Coef | HR     | p-value |
|---------|------|--------|---------|
| ANGPTL3 | -0.1200 | 0.8870 | 0.0209  |
| IL2RA   | 0.0577  | 1.0594 | 0.0401  |
| PPARA   | -0.1445 | 0.8655 | 0.0431  |
| SHC1    | 0.0105  | 1.0106 | 0.0492  |
| TGFA    | -0.0159 | 0.9843 | 0.0152  |
| TNFSF14 | 0.1075  | 1.1135 | 0.0046  |

IRGs, immune-related genes; Coef, Cox-PH coefficient; HR, Hazard Ratio.

### Table 5: Clinical characteristics of ccRCC patients included in this study.

| Variables          | Total TCGA-KIRC | Training group | Testing group | GEO cohort |
|--------------------|-----------------|----------------|---------------|------------|
|                    | (N = 504)       | (N = 252)      | (N = 252)     | (N = 39)   |
| Age (Mean ± SD)    | 60.47 ± 12.16   | 61.71 ± 11.82  | 59.24 ± 12.39 | 61.38 ± 12.77 |
| Survival time (y)  | 3.27 ± 2.18     | 3.13 ± 2.21    | 3.40 ± 2.15   | 2.99 ± 1.67   |
| Status             |                |                |               |            |
| Alive              | 339 (67.26)     | 169 (67.06)    | 170 (67.46)   | 22 (56.41)  |
| Dead               | 165 (32.74)     | 83 (32.93)     | 82 (32.54)    | 17 (43.59)  |
| Gender             |                |                |               |            |
| Male               | 331 (65.67)     | 157 (62.30)    | 174 (69.05)   |            |
| Female             | 173 (34.33)     | 95 (37.70)     | 78 (31.95)    |            |
| Stage              |                |                |               |            |
| I                  | 249 (49.70)     | 123 (49.00)    | 126 (50.40)   |            |
| II                 | 53 (10.57)      | 30 (11.95)     | 23 (9.20)     |            |
| III                | 117 (23.35)     | 58 (23.11)     | 59 (23.60)    |            |
| IV                 | 82 (16.37)      | 40 (15.94)     | 42 (16.80)    |            |
| Grade              |                |                |               |            |
| 1                  | 10 (2.01)       | 3 (1.21)       | 7 (2.80)      |            |
| 2                  | 215 (43.26)     | 110 (44.53)    | 105 (42.00)   |            |
| 3                  | 198 (39.84)     | 103 (41.70)    | 95 (38.00)    |            |
| 4                  | 74 (14.89)      | 31 (12.55)     | 43 (17.20)    |            |
| T                  |                |                |               |            |
| 1                  | 255 (50.60)     | 127 (50.40)    | 128 (50.79)   | 11 (28.21)  |
| 2                  | 65 (12.90)      | 36 (14.29)     | 29 (11.51)    | 5 (22.73)   |
| 3                  | 173 (34.33)     | 82 (32.54)     | 91 (36.11)    | 22 (56.1)   |
| 4                  | 11 (2.18)       | 7 (2.78)       | 4 (1.59)      | 1 (2.56)    |
| M                  |                |                |               |            |
| 0                  | 400 (83.68)     | 201 (84.45)    | 199 (82.92)   | 26 (66.67)  |
| 1                  | 78 (16.32)      | 37 (15.55)     | 41 (17.08)    | 13 (33.33)  |
| N                  |                |                |               |            |
| 0                  | 224 (93.33)     | 112 (93.33)    | 112 (93.33)   | 32 (82.05)  |
| 1                  | 16 (6.67)       | 8 (6.67)       | 8 (6.67)      | 7 (17.95)   |

Data are shown as n (%). T, tumor; M, metastasis; N, node.
Evaluation of the Prognostic Performance of the Clinical Prognostic Model Based on IRGs

TCGA clinical data of 504 patients with ccRCC included age, sex, stage, tumor, node, metastasis stage, and survival. These patients were randomly divided into a training (n = 252) or test (n = 252) group. Table 5 shows their clinical information. According to the risk scores of the prognostic model, patients with ccRCC were divided into a low- or high-risk group (Figure 4A). As the risk score increased, the longevity of patients decreased (Figure 4B). Figure 4C shows differential expression of the IRGs between the low- and high-risk groups. The clinical prognostic model yielded a risk score that predicted the OS rates of the low- and high-risk groups were significantly different (Figure 5A). The AUC of the ROC curve was 0.772, indicating that the prognostic features based on IRGs were highly accurate for predicting survival (Figure 5B). Furthermore, univariate analysis revealed that the risk score significantly correlated with shorter OS (HR: 2.50; 95% CI: 1.64–3.83; P < 0.001). Other clinicopathologic variables associated with poor survival included stage, and grade as well as tumor, node, and metastasis stage. Multivariate analysis indicated that the risk score served as an independent prognostic factor (HR: 2.20; CI: 1.33–3.63, P = 0.002) (Figures 6A,B, Table 6).

Validation of the Clinical Prognostic Model

To determine whether the clinical prognostic model was reliable when applied to different populations, we used the same formula to evaluate the test group and the GEO cohort (GSE29609), which was consistent with the results of the training group. The GSE29609 data include 39 patients with ccRCC (Table 5). Patients were divided into high- or low-risk groups according to the risk value of the model (Figures 4D,G). Increased risk was associated with more deaths (Figures 4E,H). The results show further that the prediction potential of the clinical prognostic model was suitable for different populations. Figures 4F,I show the expression data of selected IRGs for different risk groups. Furthermore, the probability of survival of the high-risk group was lower than that of the low-risk group (Figures 5C,E). Next, we evaluated the accuracies of the clinical prognostic model applied to the test group and GEO cohort, for which the AUCs of the ROC curve were 0.678 and 0.781, respectively (Figures 5D,F). These results indicate that the clinical prognostic model accurately predicted the prognosis of patients with ccRCC.

Clinical and Immune Correlations of the Prognostic Model

The correlation between the IRGs analyzed using the clinical prognostic model with clinical and demographic characteristics was analyzed as a function of age, sex, stage, and TNM stage (Figure 7). Furthermore, to determine whether the immune prognostic model accurately reflected the state of the tumor immune microenvironment, we analyzed the relationship between risk scores and immune cell infiltration. The results show that the risk score was significantly related to CD8+T
FIGURE 5 | Evaluation of the clinical prognostic model. (A,C,E) The risk scores of the clinical prognostic model predict survival. (B,D,F) The receiver operating characteristic (ROC) curve of survival-dependent receiver verifies the prognostic value of the model.

TABLE 6 | Univariate analysis and multivariate analysis of the correlation between the risk score calculated by the clinical prognosis model and OS.

| Clinicopathologic | Univariate analysis | Multivariate analysis |
|------------------|---------------------|----------------------|
|                  | HR (95%CI)          | p-value              | HR (95%CI)          | p-value              |
| Age              | 1.00 (0.97–1.02)    | 0.765                | 1.49 (0.84–2.65)    | 0.174                |
| Gender           | 0.85 (0.45–1.60)    | 0.616                | 0.67 (0.20–2.25)    | 0.520                |
| Grade            | 2.86 (1.72–4.75)    | <0.001               | 2.01 (0.62–6.47)    | 0.242                |
| Stage            | 1.90 (1.44–2.51)    | <0.001               | 5.14 (0.87–30.35)   | 0.071                |
| T                | 2.31 (1.56–3.41)    | <0.001               | 2.64 (0.66–10.66)   | 0.712                |
| M                | 3.79 (1.91–7.52)    | <0.001               | 2.20 (1.33–3.63)    | 0.002                |
| N                | 4.47 (1.31–15.19)   | 0.016                |                     |                      |
| Risk score       | 2.50 (1.64–3.83)    | <0.001               |                     |                      |

Bold values indicate P < 0.05. HR, hazard ratio; CI, confidence interval. T, Tumor; N, Node; M, Metastasis.

cells (p < 0.001), neutrophils (p < 0.001), and dendritic cells (p < 0.001) (Figure 8).

DISCUSSION

The role of IRGs in tumorigenesis and development is established. However, systematic, comprehensive data that identify their roles in patients with ccRCC are insufficient. To address this deficiency in our knowledge, here we analyzed the ccRCC dataset of TCGA to establish a clinical prognostic model employing differentially expressed IRGs that accurately predicted the clinical outcomes of patients according to their clinicopathological characteristics. Moreover, these IRGs are closely associated with the occurrence and development of ccRCC and therefore may serve as significant clinical biomarkers. These results show that our clinical prognostic model predicted patients’ outcomes as well as identified potential targets of immunotherapy.

Specifically, we identified 15 IRGs closely related to the survival of patients, including six protective factors and nine risk factors. Functional enrichment analysis showed that these IRGs are significantly associated with response to receptor ligand
FIGURE 6 | (A) Univariate analysis revealed that the risk score correlated with shorter OS, stage, grade, and TNM. (B) Multivariate analysis revealed that the risk score served as an independent prognostic factor.

activity. To improve the accuracy of the clinical prognostic model, we used the Lasso Cox regression model to identify IRGs with the greatest prognostic value. Moreover, to study the molecular mechanisms that explain the possible clinical value of these IRGs, we established a TF-mediated network that considered significant differentially expressed TFs regulated by these IRGs. The regulatory network contained 17 TFs and 10 IRGs. Our TF–IRG regulatory network will provide guidance for future mechanistic analyses.

The present clinical prognostic model comprised six IRGs with prognostic significance. For example, angioopoietin-like proteins (ANGPTLs) (24) mediate lipid metabolism, inflammation, cancer cell infiltration, and hematopoietic stem cell expansion (24–28). Low levels of ANGPTL3 in RCC tissue are associated with poor prognosis (29), and ANGPTL3 inhibits metastasis of RCC by regulating the activities of MMPs and epithelial-mesenchymal transition (EMT)-related pathways (29). SHC1 is expressed at higher levels in RCC tissues compared with normal tissues, suggesting its requirement for the progression of ccRCC (30). SHC1 regulates PTRF through the AKT pathway to contribute to the occurrence and development of ccRCC (30).

Signaling through NF-κB-mediated pathways promotes tumor cell proliferation, inhibits apoptosis, induces angiogenesis and the EMT, and promotes distant metastasis. The activation of NF-κB may reshape local metabolism and energize the immune system, thereby promoting tumor growth (31, 32). TNFSF14 induces the noncanonical NF-κB pathway in certain types of cancer cells to promote tumor development (33). The nuclear transcription factor peroxisome proliferator-activated receptor-α (PPARA), a key mediator of lipid metabolism, serves as a
The high levels of IL2RA in activated circulating immune cells and Tregs is exploited for IL-2 immunotherapy of tumors and autoimmune diseases; and certain polymorphisms of IL2RA are related to the risk of kidney cancer (35, 36). Thus, these IRGs therefore provide a new direction for our research.
To evaluate the prognostic value of our clinical prognostic model, we determined the OS of patients with ccRCC in the training group. The prognostic model classified these patients into high- or low-risk groups for shorter survival according to risk scores. Moreover, when we generated risk curves by combining the changes in levels of six IRGs with clinical parameters, and by combining the risk scores of the prognostic model, we were able to monitor the progression of ccRCC. ROC curves indicated that high accuracy of the clinical prognostic model. All results were verified using a testing group and the GEO cohort. Multivariate analysis further confirmed that the risk score served as an independent predictor of OS of patients with ccRCC. Moreover, the prognostic model predicted the survival of patients as well as disease progression. Thus, this model will likely serve as a valuable tool to evaluate the prognosis of patients with ccRCC.

Moreover, our clinical prognostic model showed good clinical feasibility. For example, the six IRGs performed moderately for predicting prognosis and were associated with age, sex, grade, stage, and TNM stage. To analyze tumor–immune interactions, it is essential to characterize immune infiltration. Our analysis shows that the levels of the six IRGs positively correlated with the infiltration of neutrophils, dendritic, and CD8+ T cells. The role of neutrophils in cancer is multifactorial, and they participate in different stages of cancer development, including occurrence, growth, proliferation, and metastasis (37, 38). Furthermore, neutrophils promote tumor proliferation by weakening the immune system (39). Dendritic cells are required for the immune response through attracting antitumor T cells in the TME. However, during tumor development, dendritic cells may convert from immunostimulators to immunosuppressors (40). These results suggest that high-risk patients harbor relatively higher numbers of infiltrating dendritic cells, CD8+ T cells, and neutrophils. Moreover, our results suggest that these six IRGs may predict increased immune cell infiltration.

Previously, Ghatalia et al. and Wang et al. reported the ccRCC immune model, but the research of Ghatalia et al. was mainly based on ccRCC patients who received nephrectomy, and discussed the relationship between the characteristics of tumor infiltrating immune cells and the recurrence rate of local renal cancer (41). The difference is that our study is based on ccRCC patients and established a clinical immune gene model to predict the clinical prognosis of ccRCC patients. Another analysis of TGCA RCC data identified a prognostic 6-DEG classifier, including genes encoding IL21R, ATP6V1C2,
GBP1, P2RY10, GBP4, and TNNC2 (42). Further analysis using this model revealed significant associations between immune/stromal scores and clinicopathological staging. The expression patterns of these genes expressed in the tumor microenvironment provide a powerful indicator of prognosis of patients with RCC. The differences in predictive IRGs identified by Wang et al. (42) Our present study may be explained by the former’s use of the ESTIMATE package of R to score the immune/stromal of TCGA samples and then to screen differentially expressed genes using the Lasso Cox regression model to build a prognostic six gene-based clinical model to predict the survival of patients with ccRCC. In contrast, here we screened for differentially expressed IRGs acquired from the ImmPort database, and we then identified IRGs related to survival among the differentially expressed genes and used the Lasso Cox regression model to select IRGs with the highest ability to predict prognosis to construct the prognostic model. Furthermore, our prognostic model was validated using TCGA and GEO data, which yielded consistent, stable, and universal results.

In conclusion, our study identified and validated a clinical prognostic model comprising six IRGs, which served as an independent prognostic factor for patients with ccRCC. Moreover, the prognostic significance of this model may contribute to monitoring ccRCC occurrence and to predict prognosis. Our results provide new insights into approaches to develop new immunotherapies for ccRCC.

REFERENCES

1. Jemal A, Bray F, Center MM, Ferlay J, Forman D, Mathers C. (2011) 62:60–9. doi: 10.3322/caac.200107
2. Capitanio U, Montorsi F. Renal cancer. (2016) 387:894–906. doi: 10.1016/S0140-6736(15)00046-X
3. Yuan J, Dong R, Liu F, Zhai L, Liu Y, Wei J, et al. The mir-183/182/96
cluster functions as a potential carcinogenic factor and prognostic factor in kidney renal clear cell carcinoma. Exp Ther Med. (2019) 17:2457–64. doi: 10.3892/etm.2019.7221
4. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. (2005) 353:2477. doi: 10.1056/NEJMra041372
5. Iyengar NM, Guclalp A, Dannenberg AJ, Hudis CA. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol. (2016) 34:4270–6. doi: 10.1200/JCO.2016.67.4283
6. Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. (2019) 18:10. doi: 10.1186/s12943-018-0928-4
7. Li B, Cui Y, Diehn M, Li R. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous nonsmall cell lung cancer. JAMA Oncol. (2017) 3:1529. doi: 10.1001/jamaoncol.2017.1609
8. Yoshihara K, Shamaradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. (2013) 4:2612. doi: 10.1038/ncomms3862
9. Jia D, Li S, Li D, Xue H, Yang D, Liu Y. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging. (2018) 10:592–605. doi: 10.18632/aging.101415
10. Wu J, Xu WH, Wei Y, Qu YY, Zhang HL, Ye DW. An integrated score and nomogram combining clinical and immunohistochemistry factors to predict high ISUP grade clear cell renal cell carcinoma. Front Oncol. (2018) 8:634. doi: 10.3389/fonc.2018.00634
11. Xu WH, Qu YY, Wang J, Wang HK, Wan FN, Zhao JY, et al. Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients. J Cancer. (2019) 10:4522–31. doi: 10.7150/jca.30989
12. Alonso MH, Aussó S, Lopez-Doriga A, Cordero D, Guinó E, Solé X, et al. Comprehensive analysis of copy number aberrations in microsatellite stable colon cancer in view of stromal component. Br J Cancer. (2017) 117:421–3. doi: 10.1038/bjc.2017.208
13. Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, et al. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. Sci. (2017) 6:e27861. doi: 10.7554/eLife.27861
14. Bhattacharya S, Andorf S, Gomes L, Dunn P, Schilder H, Pontius J, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res. (2014) 58:234–9. doi: 10.1007/s12026-014-8516-1
15. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. (2010) 26:139–40. doi: 10.1093/bioinformatics/btp616
16. Liang HW, Ye Z-H, Yin S, Mo W-J, Wang H, Zhao J-C, et al. Comprehensive insights into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma. Oncotargets Ther. (2017) 10:3405–19. doi: 10.2147/OTT.S13843
17. Zhang Y, Huang JC, Cai KT, Yu XB, Chen YR, Pan WY, et al. Upregulation of HOXA11 during the progression of lung adenocarcinoma detected via multiple approaches. Int J Mol Med. (2018) 42:6250–64. doi: 10.3892/ijmm.2018.3826

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data can be found in The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/) and Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/).

AUTHOR CONTRIBUTIONS

SR, WW, and HS wrote the manuscript. CZ conducted bioinformatics analyses. MS and YW collected and processed data. XZ and HH prepared figures and tables. BL prepared the literature search and the bibliography, and references. ZW designed the article. CC reviewed the final draft of the manuscript.

FUNDING

This project supported by the General project of Cancer Hospital Affiliated to Nanjing Medical University (No. ZM201803) and the National Natural Science Foundation of China (Grant No. 81902334).

ACKNOWLEDGMENTS

We thank H. Nikki March, PhD, from Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.
19. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. (2012) 16:284–7. doi: 10.1089/omi.2011.0118
20. Damian S, Andrea F, Stefan W, Kristoffer F, Davide H, Jaime HC, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. (2014) 43:D447–52. doi: 10.1093/nar/gku1003
21. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. (2003) 13:2498–504. doi: 10.1101/gr.1239303
22. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. (2017) 77:e108–10. doi: 10.1158/0008-5472.CAN-17-0307
23. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. (2000) 56:337–44. doi: 10.1111/j.0006-341x.2000.00337.x
24. Tai H, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med. (2008) 18:6–14. doi: 10.1016/j.tcm.2007.10.003
25. Galaup A, Cazes A, Jan SL, Philippe J, Connault E, Coz EL, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA. (2004) 103:18721–6. doi: 10.1073/pnas.0609025103
26. Kersten S. Regulation of lipid metabolism via angiopoietin-like proteins. Biochem Soc Transact. (2005) 33:1059. doi: 10.1042/BST20051059
27. Tabata M, Kadomatsu T, Fukuhara S, Miyata K, Ito Y, Endo M, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and obesity-related systemic insulin resistance. Cell Metab. (2009) 10:178–88. doi: 10.1016/j.cmet.2009.08.003
28. Kuo TC, Tan CT, Chang YW, Hong CC, Kuo M-L. Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility. J Clin Investig. (2013) 123:1082–93. doi: 10.1172/JCI6044
29. Zhao T, Liang X, Chen J, Bao Y, Wang A, Gan X, et al. ANGPTL3 inhibits renal cell carcinoma metastasis by inhibiting VASP phosphorylation. Biochem Biophys Res Commun. (2019) 516:880–7. doi: 10.1016/j.bbrc.2019.06.120
30. Zhao Y, Wang Y, Zhao E, Tan Y, Geng B, Kang C, et al. PTRA/CAV1, regulated by SHC1 through the EGFR pathway, is found in urine exosomes as a potential biomarker of ccRCC. Carcinogenesis. (2019) 41:274–83. doi: 10.1093/carcin/bgy147
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013
32. Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res. (2014) 2:823–30. doi: 10.1158/2326-6066.CIR-14-0112
33. D’Ignazio L, Batie M, Rocha S. TNFSF14/LIGHT, a non-canonical NF-κB stimulus, induces the HIF pathway. Cells. (2018) 7:102. doi: 10.3390/cells7080102
34. Wu F, Wu S, Gou X. Identification of biomarkers and potential molecular mechanisms of clear cell renal cell carcinoma. Neoplasma. (2018) 65:242–52. doi: 10.4149/neuro_2018_170511N342
35. Motzer RJ, Figlin RA, Martini JF, Hariharan S, Agarwal N, Li CX, et al. Germline genetic biomarkers of sunitinib efficacy in advanced renal cell carcinoma: results from the RENAL EFFECT trial. Clin Genitourin Cancer. (2017) 15:526–33. doi: 10.1016/j.clgc.2017.02.006
36. Jia Z, Zhang Z, Yang Q, Deng C, Li D, Ren L. Effect of IL2RA and IL2RB gene polymorphisms on lung cancer risk. Int Immunopharmacol. (2019) 74:105716. doi: 10.1016/j.intimp.2019.105716
37. Coffelt SB, Wellenstein MD, De Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. (2016) 16:431–46. doi: 10.1038/nrc.2016.52
38. Zhang L, Romero P. Metabolic control of CD9(+) T cell fate decisions and antitumor immunity. Trends Mol Med. (2018) 24:30–48. doi: 10.1016/j.tmm.2017.11.005
39. Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer. (2017) 16:137. doi: 10.1186/s12943-017-0707-7
40. Engelhardt J, Boldajipour B, Beemiller P, Pandurangi P, Sorensen C, Werb Z, et al. Marginalizing dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell. (2012) 21:402–17. doi: 10.1016/j.ccc.2012.01.008
41. Ghatalia P, Gordesky J, Kuo F, Dalaimi E, Plimack E. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. J Immunother Cancer. (2019) 7:139. doi: 10.1186/s40425-019-0735-5
42. Wang S, Zheng X, Chen X, Shi X, Chen S. Prognostic and predictive value of immune/stromal-related gene biomarkers in renal cell carcinoma. Oncol Lett. (2020) 20:308–16. doi: 10.3892/ol.2020.11574

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.